GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...
GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable ...
The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes ...
DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom ...
New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.
13d
DexCom outlines 2026 revenue growth of 11%-13% with G7 15 Day rollout and international expansion
DexCom expects 2026 total revenue to be in a range of $5.16 billion to $5.25 billion, representing growth of 11% to 13% for the year. Sylvain indicated, "This guidance assumes continued strong ...
Urinary tract infections (UTIs) are among the most common bacterial infections, with catheter-associated UTIs accounting for ...
StockStory.org on MSN
The 5 most interesting analyst questions from DexCom’s Q4 earnings call
DexCom’s fourth quarter results reflected ongoing momentum in both product innovation and international expansion. Management ...
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include ...
DexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the approval of the company’s upcoming 15-day G7 continuous glucose monitor (CGM).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results